Long-Term Experience With Ibrutinib in CLL
ByWilliam Wierda, MD, PhD, University of Texas MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,Ehab Atallah, MD, Medical College of Wisconsin,Steven Coutre, MD, Stanford University Medical Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center at Columbia University,Jennifer Woyach, MD, Ohio State University
Jennifer Woyach, MD, discusses her experience using ibrutinib for chronic lymphocytic leukemia (CLL) in the first-line setting.